In the last decade, many studies have focused on the role of EZH2 in GB [37,38], suggesting that its inhibition could represent a valid and alternative strategy to contrast cancer progression through apoptosis and autophagy modulation [32]. This evidence concerns the gene EZH2 and cancer.